Strategic Analysis of World Psychiatric Therapeutics Markets

SUMMARY

Strategic Analysis of World Psychiatric Therapeutics Markets

Research Overview

Loss of Patent Protection Challenges Market Growth

The imminent patent expiration for key anticonvulsants such as Neurontin (in2004), Topamax (in 2004), and Trileptal (in 2005) is expected to create a voidin the psychiatric therapeutics market. Apart from Lyrica

, lack of new anticonvulsants to counter the negative impact of patentexpiration is expected to magnify the challenge and expose the market tocompetition from generic drugs. While patent expiration is not an issue in theantipsychotics segment, pending patent protection for several products in thissegment is a major concern.

This Frost & Sullivan research evaluates the current state of thepsychiatric therapeutics market and examines the key drivers and challenges thatshape its current and future demand. This study highlights the importantresearch and development efforts in the top three psychiatric therapeuticssegments comprising anticonvulsants, antidepressants, and antipsychotics.

Huge Patient Population Drives Antidepressants Market Growth

An aging baby-boomer population has thrown open numerous opportunities in thepsychiatric therapeutics market, especially in the antidepressant segment.Anxiety markets offer a lucrative proposition for continued expansion asreflected in the growing acceptance and usage of antidepressants. "Over thelast few years, antidepressants have been witnessing greater acceptance amongthe mainstream patient population ? Primarily due to effective direct toconsumer (DTC) marketing campaigns and the newly approved indications,"says the analyst.

While the overall psychiatric therapeutics market is coming under intenseprice pressure from governmental and insurance agencies, the prices ofantidepressant drugs have been rising steadily. Additionally, increasing uptakeof Cymbalta ? A recent introduction in the antidepressant segment ? Is expectedto minimize the negative impact of patent expiration and boost the totalrevenues in the psychiatric therapeutics market.

Cost to Benefit Ratio of Atypical Antipsychotics Challenges MarketExpansion

The conversion from typical to atypical treatments has been a major drivingforce in the antipsychotics segment. Not only are atypical antipsychotics moreexpensive but studies have shown that, in terms of performance, these drugsoutstrip their typical counterparts. "However, in order to sustain growthin the market and prove attractive to patients for long-term usage, researchersneed to pay serious attention to the cost-benefit ratio of atypicalantipsychotics," explains the analyst.

The increasing penetration of newer antipsychotics ? Such as Abilify have thepotential to provide benefits comparable to leading atypical antipsychoticswithout causing the associated side effects. However, the newly approvedindications increase the use of atypical antipsychotics for treating bipolardisorders and are likely to sustain revenues in the long run.

Frost & Sullivan Growth Partnership Service

Based on extensive and in-depth research, real-world consulting work, and newtheories tested in hundreds of companies across many industries, Frost &Sullivan has evolved its Growth Partnership Services (GPS) program that providesestablished and emerging firms with powerful growth visions. Moving beyond tokenmission statements, GPS provides an actionable vision to growth consultingpartners by illustrating how key intelligence and strategic research based ondefined goals can guide day-to-day behavior and overall company direction. Thefoundation of Frost & Sullivan's GPS includes:

• Assisting companies to reach their full potential in the core business
• Providing growth strategies to help companies expand into relatedbusinesses
• Preemptively redefining the core business during market turbulence
• Applying the Frost & Sullivan framework to identify and address commonmistakes resulting from misaligned corporate strategies
• Recommending growth management strategies through continuous partnership

To maximize the potential for growth within a firm\'s internal and externalenvironment, Frost & Sullivan consultants can facilitate the creation ofstrategic programs that deliver improved market success. Frost &Sullivan\'s strengths lie in combining strategic understanding with marketexpertise and applying these with absolute commitment to its clients\' growth.

TABLE OF CONTENTS

1 STRATEGIC ANALYSIS OF WORLD PSYCHIATRIC THERAPEUTICS MARKETS

• Overview
  • Introduction
  • Disclaimer
  • Certification
  • Research Scope and Methodology
  • Study Objectives
  • Market Segmentation by Geographical Region
  • Market Segmentation by Indications
• Total Market Overview
  • Market Dynamics Overview
  • Research and Development Overview
  • Executive Quote
• Anticonvulsant Markets
  • Introduction
  • Revenues by Geographical Regions
  • Revenue Forecast by Geographical Regions
  • Revenue Split by Product
  • Demand Analysis
  • Industry Challenges
  • Market Drivers
  • Market Restraints
  • Revenue Potential
  • Product Pipeline Analysis
  • Product Analysis: Pregabalin
  • Product Analysis: Rufinamide
• Antidepressants Markets
  • Introduction
  • Revenues by Geographical Regions
  • Revenue Forecast by Geographical Regions
  • Revenue Split by Product
  • Demand Analysis
  • Percent of Treated vs. Untreated Patients
  • Industry Challenges
  • Market Drivers
  • Market Restraints
  • Product Pipeline Analysis
  • Product Analysis: Cymbalta
  • Product Analysis: DVS-233 SR
  • Product Analysis: Gepirone ER
  • Product Analysis: SR 58611
• Antipsychotic Markets
  • Introduction
  • Revenues by Geographical Regions
  • Revenue Forecast by Geographical Regions
  • Revenue Split by Product
  • Industry Challenges
  • Market Drivers
  • Market Restraints
  • Product Pipeline Analysis
  • CEO Quote
  • Product Analysis: Bifeprunox
• Competitive Landscape
  • Company Analysis
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Eli Lilly
  • Johnson and Johnson
  • Wyeth
  • Novartis
  • Forest Laboratories
  • Organon
  • Anticipating the Future
• Frost & Sullivan Awards
  • Introduction
  • Competitive Strategy Leadership Award
  • Product Innovation Award - Antipsychotic Markets
  • Product Innovation Award - Antidepressant Markets
  • Growth Strategy Leadership Award
• Decision Support Databases
  • Psychiatrics
  • Neurologists
  • Alzheimer's Patients
  • Population 65 and Above
  • Physicians
• Frost & Sullivan
  • Healthcare Team
  • Our Capabilities
  • Key Advantages
  • Our Consulting Clients
  • Growth Consulting
  • Growth Consulting Process
  • Growth Consulting Deliverables
  • Growth Partnership Service
  • Growth Partnership Service Platform